Clinical Risk Factors for Treatment Failure-A Retrospective Single Centre Analysis of Patients With Unresponsive Class IV Lupus Nephritis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
American journal of therapeutics - 29(2022), 6 vom: 23. Nov., Seite e695-e697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Mei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.01.2023 Date Revised 11.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/MJT.0000000000001278 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336884958 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336884958 | ||
| 003 | DE-627 | ||
| 005 | 20231225233146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MJT.0000000000001278 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336884958 | ||
| 035 | |a (NLM)35156362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Mei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Risk Factors for Treatment Failure-A Retrospective Single Centre Analysis of Patients With Unresponsive Class IV Lupus Nephritis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2023 | ||
| 500 | |a Date Revised 11.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 700 | 1 | |a Zhang, Yu-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Yuan-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Rui-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xue-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Ya-Xian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Juan-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of therapeutics |d 1994 |g 29(2022), 6 vom: 23. Nov., Seite e695-e697 |w (DE-627)NLM093845677 |x 1536-3686 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:6 |g day:23 |g month:11 |g pages:e695-e697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MJT.0000000000001278 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 6 |b 23 |c 11 |h e695-e697 | ||